Rezolute (RZLT)
(Delayed Data from NSDQ)
$4.35 USD
-0.02 (-0.46%)
Updated Sep 6, 2024 04:00 PM ET
Pre-Market: $5.04 +0.69 (15.86%) 8:08 AM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Price, Consensus and EPS Surprise
RZLT 4.35 -0.02(-0.46%)
Will RZLT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RZLT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for RZLT
Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why
RZLT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for RZLT
FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
Rezolute to Participate in Upcoming Investor Conferences
Rezolute initiated with a Buy at Guggenheim on potential in CHI
Rezolute initiated with bullish view at Guggenheim
Buy Rating Affirmed for Rezolute on Strong Phase 3 Progress and Positive Drug Prospects